TYRA

Tyra Biosciences, Inc. (TYRA) ESG Analysis Analysis (2026)

Invetso Score: 6.2/10 — Balanced · Last Updated: 2026-08-01

Environmental

TYRA’s disclosed R&D intensity is not available in the provided metrics, limiting evidence of environmental process efficiency versus peers in capital-intensive biotech.

The absence of reported gross profit margin and FCF margin in the supplied data reduces visibility into resource efficiency, leaving TYRA broadly in line with disclosure-limited peers.

Very low leverage can indirectly support environmental resilience by preserving flexibility for compliance-related investments, but this is not a direct environmental advantage versus peers.

No Tier 1 filing evidence was provided on emissions, energy use, or waste, so TYRA cannot be assessed as structurally stronger than peers on environmental stewardship.

Social

The provided metrics do not include workforce, safety, or patient-access disclosures, which limits assessment of TYRA’s social positioning versus clinical-stage peers.

Zero reported stock-based compensation to revenue in the supplied data suggests lower dilution pressure on employees, but this is not enough to establish a peer-leading social profile.

As a biotech issuer, TYRA’s social materiality is driven mainly by clinical-trial conduct and patient safety, yet no filing evidence was provided to compare those practices with peers.

Limited disclosure on human-capital and community factors keeps TYRA near the middle of the peer range rather than clearly advantaged or disadvantaged.

Governance

TYRA’s very low debt-to-equity ratio indicates conservative capital structure, which can reduce creditor pressure and support governance flexibility versus more levered peers.

Net debt to EBITDA is modest in the supplied data, suggesting restrained balance-sheet risk, although this does not by itself indicate stronger board oversight.

Zero stock-based compensation to revenue may imply less compensation-related dilution than peers, but the absence of broader governance disclosures prevents a stronger score.

Without filing evidence on board independence, audit controls, or shareholder rights, TYRA appears adequately governed but not clearly superior to peers.

Overall Score

TYRA’s ESG profile is broadly middle-of-pack versus peers because the supplied data show conservative leverage, but material environmental, social, and governance disclosures are limited.

Score Driver: Limited ESG Disclosure Prevents Evidence Of A Clear Peer Advantage.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Tyra Biosciences, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →